| scholarly article | Q13442814 |
| P50 | author | Kevin G. Pinney | Q39948043 |
| Ernest Hamel | Q90170386 | ||
| P2093 | author name string | Mary Lynn Trawick | |
| Tracy E Strecker | |||
| Graham J Carlson | |||
| Casey J Maguire | |||
| Jacob W Ford | |||
| P2860 | cites work | Antivascular and antitumor properties of the tubulin-binding chalcone TUB091 | Q27705273 |
| Impact of water on the cis-trans photoisomerization of hydroxychalcones | Q30619609 | ||
| In-solution and on-plate light-catalyzed E/Z isomerization of cyclic chalcone analogues. Lipophilicity of E- and Z-2-(X-benzylidene)-1-benzosuberones | Q30997368 | ||
| A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models | Q33484368 | ||
| A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent | Q33641044 | ||
| Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503 | Q34491366 | ||
| Targeting tumour vasculature: the development of combretastatin A4. | Q34572069 | ||
| The biology of the combretastatins as tumour vascular targeting agents | Q34680614 | ||
| The role of chalcones in suppression of NF-κB-mediated inflammation and cancer | Q34682265 | ||
| A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment | Q34765364 | ||
| Relationship between structure of conjugated oxime esters and their ability to cleave DNA. | Q35025819 | ||
| Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin | Q35094121 | ||
| Vascular targeting agents as cancer therapeutics | Q35647684 | ||
| Vascular-targeting therapies for treatment of malignant disease. | Q35805639 | ||
| Pharmaceutical design of antimitotic agents based on combretastatins. | Q36126721 | ||
| Disrupting tumour blood vessels | Q36146900 | ||
| Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS. | Q36271413 | ||
| Medicinal chemistry of combretastatin A4: present and future directions. | Q36488159 | ||
| Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization | Q36788673 | ||
| Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents | Q36839418 | ||
| An overview of tubulin inhibitors that interact with the colchicine binding site | Q36885540 | ||
| An Amino-Benzosuberene Analogue That Inhibits Tubulin Assembly and Demonstrates Remarkable Cytotoxicity | Q36929601 | ||
| Antineoplastic agents. 552. Oxidation of combretastatin A-1: trapping the o-quinone intermediate considered the metabolic product of the corresponding phosphate prodrug. | Q37373163 | ||
| Antimitotic chalcones and related compounds as inhibitors of tubulin assembly | Q37411214 | ||
| Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies | Q37534993 | ||
| Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents. | Q37670789 | ||
| Recent developments in biological activities of chalcones: a mini review | Q38241278 | ||
| Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin | Q38508789 | ||
| Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. | Q38722440 | ||
| Recent advances of cytotoxic chalconoids targeting tubulin polymerization: Synthesis and biological activity. | Q38869618 | ||
| Eco-friendly synthesis and antiproliferative evaluation of some oxygen substituted diaryl ketones. | Q39108117 | ||
| Synthesis and biological evaluation of enantiomerically pure cyclopropyl analogues of combretastatin A4. | Q39201497 | ||
| Development of combretastatins as potent tubulin polymerization inhibitors. | Q39275685 | ||
| Chalcone: A Privileged Structure in Medicinal Chemistry | Q39295083 | ||
| Design, synthesis and biological evaluation of novel chalcone derivatives as antitubulin agents | Q39364750 | ||
| Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities | Q39780417 | ||
| Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs | Q39781025 | ||
| Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones | Q39786407 | ||
| Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity | Q39786412 | ||
| Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy | Q39947985 | ||
| Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography. | Q40721982 | ||
| Potent antimitotic and cell growth inhibitory properties of substituted chalcones | Q40984969 | ||
| Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines | Q41679901 | ||
| Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. | Q42203168 | ||
| Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents. | Q46730937 | ||
| Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis | Q48235229 | ||
| Sulforhodamine B colorimetric assay for cytotoxicity screening. | Q51032435 | ||
| Evaluation of multifunctional synthetic tetralone derivatives for treatment of Alzheimer's disease. | Q51109990 | ||
| Synthesis of α,β-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells. | Q51419901 | ||
| An efficient synthesis of enamides from ketones. | Q53881700 | ||
| Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents | Q57574255 | ||
| 2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity | Q67267559 | ||
| Chalcones: a new class of antimitotic agents | Q68835517 | ||
| 2'-substituted chalcone derivatives as inhibitors of interleukin-1 biosynthesis | Q70724752 | ||
| Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17 | Q71082840 | ||
| Pyridyl-substituted tetrahydrocyclopropa[a]naphthalenes: highly active and selective inhibitors of P450 arom | Q72317765 | ||
| Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones | Q77353251 | ||
| The development of chalcones as promising anticancer agents | Q79449777 | ||
| Effects of alpha-substitutions on structure and biological activity of anticancer chalcones | Q80204612 | ||
| Conformationally restricted anti-plasmodial chalcones | Q81193793 | ||
| Synthesis, antiproliferative activity and inhibition of tubulin polymerization by anthracenone-based oxime derivatives | Q84402431 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1445-1456 | |
| P577 | publication date | 2019-06-04 | |
| P1433 | published in | MedChemComm | Q3303881 |
| P1476 | title | Synthesis and biological evaluation of structurally diverse α-conformationally restricted chalcones and related analogues | |
| P478 | volume | 10 |
Search more.